poisar

Stock

Unicycive Therapeutics, Inc. UNCY

$5.47+0.74%

Overview

UNCY market data

Price History

UNCY price chart · 1M
O
5.47
H
5.52
L
5.45
C
5.47
Vol
16,221.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$5.47
Previous Close
$5.43
Day High
$5.52
Day Low
$5.45
52 Week High
$8.74
52 Week Low
$3.99
7 Day Return
+0.46%
30 Day Return
+10.84%
90 Day Return
-25.68%
1 Year Return
-23.60%
Daily Notional Volume
$88.7K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$5.48
Diluted earnings per share over the trailing twelve months.
Beta
1.76
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-4,159.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.71 – $8.74
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $137.2M · P/B 4.11 · P/S 31.15.

Company News

10 captured
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15Benzinga · Aug 20, 2026, 3:38 PM
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25Benzinga · Aug 13, 2026, 2:12 PM
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20Benzinga · Aug 13, 2026, 1:56 PM
8-K filing — Unicycive Therapeutics, Inc. (UNCY)SEC EDGAR · Aug 12, 2026, 12:04 PM
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) EstimateBenzinga · Aug 12, 2026, 10:43 AM
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading WarningsBenzinga · Jul 16, 2026, 5:29 PM
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud InvestigationGlobenewswire Inc · Jul 13, 2026, 7:15 PM
ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn MoreGlobenewswire Inc · Jul 8, 2026, 10:15 PM
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13Benzinga · Jul 1, 2026, 3:40 PM
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50Benzinga · Jul 1, 2026, 2:00 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock